Correction: Chronic immune checkpoint inhibitor pneumonitis

Correction: Chronic immune checkpoint inhibitor pneumonitis

Saved in:

Bibliographic Details
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-10-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/8/2/e000840corr1.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Chronic immune checkpoint inhibitor pneumonitis
by: Julie R Brahmer, et al.
Published: (2020-05-01)

Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment
by: Giampaolo Tortora, et al.
Published: (2020-10-01)

Krebs von den Lungen-6 surveillance in immune checkpoint inhibitor-induced pneumonitis
by: Isamu Okamoto, et al.
Published: (2024-12-01)

Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis
by: Yan Huang, et al.
Published: (2020-10-01)

Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy
by: Michael B Atkins, et al.
Published: (2020-05-01)

Correction: Immune checkpoint inhibitor-associated celiac disease
Published: (2020-10-01)

Clinical characteristics and biomarkers of severe immune checkpoint inhibitor-related pneumonitis triggered by immunotherapy followed by radiation: a case report
by: Yan Zhu, et al.
Published: (2024-11-01)

Cyclosporine successfully treats steroid-resistant checkpoint inhibitor-related pneumonitis: a case report
by: Jiaxi Deng, et al.
Published: (2024-11-01)

Immune checkpoint inhibitor-related pneumonitis following discontinuation of pembrolizumab in a patient with advanced lung adenocarcinoma: a case report and literature review
by: Huan Wang, et al.
Published: (2024-12-01)

Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update
by: Douglas B Johnson, et al.
Published: (2024-07-01)

Correction: Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Published: (2022-12-01)

A Case of Long-Term Survival after Checkpoint Inhibitor Pneumonitis in a Patient with Squamous Cell Lung Cancer
by: Hironori Ashinuma, et al.
Published: (2019-01-01)

Predictive biomarkers of response to immune checkpoint inhibitors
by: María Sacramento Díaz-Carrasco, et al.
Published: (2020-07-01)

Immune Checkpoint Inhibitor-Associated Transverse Myelitis
by: Ömer Faruk Turan, et al.
Published: (2024-12-01)

Subacute parkinsonism induced by immune checkpoint inhibitors
by: Lénia Silva, et al.
Published: (2024-12-01)

Efficacy of immune checkpoint inhibitors for in-transit melanoma
by: Victoria Atkinson, et al.
Published: (2020-05-01)

Immune checkpoint inhibitor-associated celiac disease
by: Jonathan Chen, et al.
Published: (2020-05-01)

Unleashing immunity against oral cancer with immune checkpoint inhibitors
by: Ajay Guru
Published: (2024-06-01)

An overview of immune checkpoint inhibitor toxicities in bladder cancer
by: Avenie Mavadia, et al.
Published: (2024-12-01)

Research progress of immune checkpoint inhibitors in ovarian cancer
by: Lingli Zhao, et al.
Published: (2024-12-01)

Resistance mechanisms to immune checkpoint inhibitors: updated insights
by: Besan H. Alsaafeen, et al.
Published: (2025-01-01)

A review of neurological complications of immune-checkpoint inhibitors
by: D. Valančius, et al.
Published: (2021-12-01)

COVID-19 and immune checkpoint inhibitors: initial considerations
by: Brian I Rini, et al.
Published: (2020-05-01)

Pericardial disease in patients treated with immune checkpoint inhibitors
by: Anju Nohria, et al.
Published: (2021-06-01)

Research progress of immune checkpoint inhibitors in the treatment of glioblastoma
by: JIA Xiaorong, et al.
Published: (2024-05-01)

Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma
by: Jarushka Naidoo, et al.
Published: (2020-10-01)

Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis
by: Michael Dougan, et al.
Published: (2020-10-01)

Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity
by: Karla A Lee, et al.
Published: (2020-10-01)

Correction: T lymphocyte-targeted immune checkpoint modulation in glioma
Published: (2020-05-01)

Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
by: Jing Wei, et al.
Published: (2024-12-01)

Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes
by: Anupam Kotwal, et al.
Published: (2019-05-01)

Multiple stellate keratitis during immune checkpoint inhibitor therapy
by: Isana Nakajima, et al.
Published: (2025-03-01)

Diabetic ketoacidosis as a complication of immune checkpoint inhibitor therapy
by: Nathan L. Haas, et al.
Published: (2023-06-01)

Risk of immune‐related pneumonitis for PD1/PD‐L1 inhibitors: Systematic review and network meta‐analysis
by: Yafang Huang, et al.
Published: (2019-05-01)

Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors
by: Yuhui Yang, et al.
Published: (2025-02-01)

Establishment of an animal model of immune‐related adverse events induced by immune checkpoint inhibitors
by: Yuan Meng, et al.
Published: (2024-07-01)

Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors
by: Maansi Joshi, et al.
Published: (2020-01-01)

Preconditioning of the immune system modulates the response of papillary thyroid cancer to immune checkpoint inhibitors
by: Yoshinori Yasuda, et al.
Published: (2022-12-01)

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
by: Andrew L Mammen, et al.
Published: (2021-07-01)

Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis
by: Jennifer Cautela, et al.
Published: (2020-10-01)